Cannabis shows modulatory effects on the gastrointestinal system through the endocannabinoid system, with emerging evidence for benefits in IBD, motility disorders, and GI malignancies, but risks include dependency, cognitive impairment, and cannabinoid hyperemesis syndrome.
Gastroenterologists, IBD specialists, GI patients considering medical cannabis.
Cannabis has both therapeutic and harmful GI effects through the endocannabinoid system
What the researchers found
Cannabis has modulatory effects on the GI endocannabinoid system with emerging evidence for benefits in inflammatory bowel disease, motility disorders, GI malignancies, and symptom management (nausea, anorexia, abdominal pain). Risks include dependency, cognitive impairment, and cannabinoid hyperemesis syndrome. The review proposes dosing strategies for gastroenterologist guidance.
Why it matters
Many GI patients already use cannabis without their gastroenterologist's knowledge. This review gives GI specialists a framework for evaluating evidence, discussing risks, and considering dosing if they choose to recommend medical cannabis.
The numbers in context
No specific quantitative outcomes. Review covers IBD, motility disorders, GI malignancies, nausea/vomiting, anorexia, and abdominal pain.
How the study worked
Narrative review of animal and human studies on cannabis in gastrointestinal diseases, including discussion of dosing strategies and patient counseling approaches.
What this study cannot tell us
Narrative review without systematic methodology. Evidence for most GI applications remains preliminary. Dosing recommendations are based on limited data. Side effect profile may be undercharacterized for chronic GI conditions.
How to read the evidence
Narrative review of mixed-quality evidence. Proposes dosing guidance but acknowledges limited supporting data.
When this study was published
Published in 2023.
The bigger picture
Gastroenterology has a unique relationship with cannabis: the endocannabinoid system heavily regulates GI function, cannabis can treat GI symptoms, but cannabis can also cause a GI condition (cannabinoid hyperemesis). This dual nature makes informed prescribing especially important.
Questions still open
- Would gastroenterologist-directed cannabis use reduce rates of cannabinoid hyperemesis by enabling better dose management?
- Which GI condition has the strongest evidence for cannabis benefit?
Common questions
Can cannabis help GI conditions?
What are the GI risks of cannabis?
Read the original research
Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns.
World journal of clinical cases, 11(18), 4210-4230
Citation
Samuel, Sonia; Michael, Mark; Tadros, Micheal. (2023). Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns.. World journal of clinical cases, 11(18), 4210-4230. https://doi.org/10.12998/wjcc.v11.i18.4210
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk